Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults
Press Releases (Glenmark)
-
-
Glenmark commemorates World Heart Month by organizing Public Hypertension Awareness Campaigns across the Country
-
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination
-
Glenmark launches Ryaltris®-AZ at an affordable price in India
-
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination
-
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray
-
Dr. Reddy’s to acquire select Anti-Allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan
-
Glenmark introduces NINDANIB (Nintedanib) for the treatment of Pulmonary Fibrosis in India
-
Glenmark introduces higher strength (400 mg) of FabiFlu(R) to reduce pill burden of COVID-19 treatment
-
Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19
-
COVID-19: Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs
-
Glenmark introduces 3-in-1 inhaler therapy for COPD
